Atlanta Joins the Ebola Watchlist: How One Airport and One Biotech Are Keeping Calm and Carrying On -( $DAL $GOVX $XBI ) by John F. Heerdink, Jr. 2 days ago Read more The Insulin Pump That Could Spark a Bidding War: Modular Medical’s Pivot Targets Millions Still on Manual Injections -( $ABT $JNJ $MDT $MMED $MODD $PODD $TNDM ) by John F. Heerdink, Jr. 4 days ago Read more Stifel Places Target On Eupraxia During National Eosinophil Awareness Week -( $EPRX $SNY $REGN $TAK ) by John F. Heerdink, Jr. May 20, 2026 Read more Reverse Merger, Forward Thinking: InMed, Mentari and the Billion‑Patient Migraine Market -( $INM ) by John F. Heerdink, Jr. May 19, 2026 Read more Not Another AI Toy: How Commure Built a $6 Billion Healthcare Workhorse by John F. Heerdink, Jr. May 19, 2026 Read more Eupraxia, Dupixent, and the Race to Redefine EoE Care -( $EPRX $REGN $SNY ) by John F. Heerdink, Jr. May 18, 2026 Read more Amwell, Meet Mother Nature: Why Virtual Care May Thrive on Real‑World Green Space -( $AMWL ) by John F. Heerdink, Jr. May 18, 2026 Read more From Viral Load to Order Book: What the Congo Ebola Outbreak Could Mean for Vaccine Names -( $MRK $JNJ $GOVX ) by John F. Heerdink, Jr. May 18, 2026 Read more FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI ) by John F. Heerdink, Jr. May 16, 2026 Read more Healthcare’s Quiet Reboot: Why P3 and Amwell Are Leaning Into the Hard Work -( $AMWL $PIII ) by John F. Heerdink, Jr. May 15, 2026 Read more Read more
